Testosterone Cypionate Hair and Skin Changes: What to Expect and How to Manage Them

Testosterone cypionate is an injectable, long-acting ester of testosterone (brand example: Depo-Testosterone), FDA-approved for testosterone replacement in men with confirmed hypogonadism. It is not the same molecule as testosterone enanthate or as compounded subcutaneous testosterone products, though all three raise circulating testosterone and can produce similar downstream skin and hair effects.

Direct answer: Testosterone cypionate does not create androgenic alopecia in a man whose follicles are not genetically primed for it, but in men who carry that genetic susceptibility, it can accelerate scalp hair miniaturization while simultaneously increasing acne, facial oiliness, and body or beard hair growth. The mechanism for all of these effects is the same: testosterone is converted locally in skin by the enzyme 5-alpha-reductase into dihydrotestosterone (DHT), and DHT acts differently depending on where the follicle or gland is located. This pattern is biologically well established; the exact incidence rates, timelines, and treatment-response numbers below vary across studies and populations, so they should be treated as general ranges rather than individual predictions.

How testosterone cypionate reaches skin and hair follicles

Testosterone cypionate is dissolved in oil and injected intramuscularly, typically every one to two weeks for hypogonadism, at doses individualized by a prescriber. Once the ester is cleaved, free testosterone circulates and enters skin tissue, where two isoenzymes of 5-alpha-reductase do most of the work: type 1, concentrated in sebaceous glands, and type 2, concentrated in hair follicles. Both convert testosterone into DHT, which binds the androgen receptor more avidly than testosterone itself. This is why cutaneous effects can appear even when serum testosterone is only modestly elevated: skin and scalp tissue can generate and respond to androgen signal locally, not just in proportion to what is measured in blood.

Why post-injection timing matters for acne

Weekly testosterone cypionate injections produce a serum peak in the days after injection and a trough near the end of the interval. Some patients notice acne flares clustering in the window after an injection, consistent with a transient androgen surge. Splitting a weekly dose into two smaller injections spaced across the week is a commonly used strategy to flatten this peak-and-trough pattern; it is a reasonable, low-risk adjustment to discuss with a prescriber, though it should be treated as a management option rather than a guaranteed fix, since controlled comparative data on skin outcomes specifically are limited.

Why two men on the same dose can have different skin outcomes

Individual sensitivity to androgens varies. This is generally attributed to differences in androgen receptor activity and skin type, and it means family and personal history of acne or pattern hair loss is more predictive of a patient's skin response than the milligram dose alone. Asking about that history before the first prescription is a reasonable clinical step, even though it cannot fully predict outcomes.

Acne and oily skin

Acne is among the more commonly discussed cutaneous effects of testosterone therapy, and it makes biological sense given that sebaceous gland activity is androgen-driven. Reported incidence figures vary widely across studies and clinical populations depending on formulation, dose, follow-up length, and how acne was defined and measured; a specific incidence percentage should not be quoted as a fixed expectation for an individual patient, and any number cited elsewhere should be checked against the original trial or registry report before being treated as authoritative.

A practical treatment ladder, based on standard dermatologic approaches to androgen-related acne rather than testosterone-specific trials:

• Mild comedonal acne often responds to a topical retinoid or benzoyl peroxide.
• Moderate inflammatory acne may warrant a topical antibiotic or a time-limited course of an oral antibiotic, prescribed and monitored by a clinician.
• Severe or scarring acne is a decision point that should involve the prescribing clinician and, often, a dermatologist. Options include dose reduction, switching to a formulation with a flatter pharmacokinetic profile (such as a transdermal gel), or, in refractory cases, isotretinoin under specialist supervision.

Oily skin without frank acne is common and typically manageable with a gentle, non-stripping cleansing routine. Severe oiliness sometimes improves with the dose-splitting approach described above, but this should be confirmed with the prescriber rather than self-adjusted.

Hair loss and androgenic alopecia

Androgenic alopecia (AGA) is a genetically determined, androgen-dependent process. DHT shortens the growth phase of scalp follicles that carry the genetic susceptibility, gradually converting terminal hairs into fine, short vellus-like hairs. The general clinical consensus, reflected across dermatology literature on androgen therapy, is that testosterone treatment does not create AGA in a man without the underlying genetic predisposition, but it can accelerate the process, sometimes by years, in someone who already carries it.

Patients who are genetically predisposed sometimes notice increased shedding weeks to a few months after starting therapy, which can represent a transitional shift of follicles out of the growth phase rather than immediate permanent loss. Shedding that continues well beyond that early window is more consistent with ongoing miniaturization and is a reasonable trigger to discuss treatment rather than wait.

What has real evidence behind it

• Finasteride (a 5-alpha-reductase type 2 inhibitor) is the best-studied oral option for slowing or partially reversing AGA. It substantially lowers scalp DHT without meaningfully lowering serum testosterone, which is why it is generally considered compatible with continuing TRT. Individual trial results (percentage DHT reduction, hair count changes) vary by study design and should be verified against the primary publication rather than treated as fixed numbers for every patient.
• Dutasteride inhibits both type 1 and type 2 5-alpha-reductase and is used off-label for AGA. It suppresses DHT more completely than finasteride, which is a stronger effect but also an off-label use requiring an individualized risk discussion.
• Topical minoxidil works through a mechanism independent of androgen signaling (it prolongs the growth phase) and is considered additive to finasteride rather than redundant with it. It is FDA-approved for androgenetic alopecia, not specifically for TRT-associated hair thinning, but the underlying process being treated is the same.
• Low-level laser therapy devices are FDA-cleared for androgenetic alopecia in some models; evidence quality and effect size vary by device and study, and this is a supplementary option rather than a primary treatment.

None of these interventions reliably regrows follicles that have already been lost for years; they work best at slowing or partially reversing early-to-moderate miniaturization. This is the central asymmetry of TRT-related hair loss: prevention and early intervention are far more effective than any strategy attempted after advanced thinning.

Body hair, beard growth, and gender-affirming therapy

Body and beard follicles respond to DHT in the opposite direction from scalp follicles: they are stimulated rather than miniaturized. This is a genuine biological paradox, not a contradiction, and it is explained by different androgen receptor and co-regulator expression at different follicle sites. Increases in chest, abdominal, back, and facial hair commonly develop over months and can continue for a few years before plateauing. This is an expected pharmacologic effect, not a side effect requiring treatment for most patients.

For transgender men using testosterone cypionate for gender-affirming hormone therapy, virilizing changes including facial hair growth, increased body hair, and scalp hair changes are an expected and often desired part of treatment, and full facial and body hair effects can take several years to reach their maximum extent. The same DHT-dependent scalp thinning risk applies to genetically predisposed transgender men, and the same preventive options (finasteride, minoxidil) are available, though some patients choose to delay or decline them given their virilization goals. This is a value-based decision that should be made with the prescribing clinician, not a default recommendation either way.

Injection-site skin reactions

Testosterone cypionate is formulated in an oil vehicle (commonly cottonseed oil) and injected intramuscularly or, in some regimens, subcutaneously. The FDA prescribing information for testosterone cypionate injection describes local injection-site reactions, including erythema, induration, and tenderness, as a recognized adverse effect, per the manufacturer's prescribing information. Most such reactions are self-limited. A nodule or reaction that persists beyond about two weeks is worth evaluating for oil-vehicle hypersensitivity; switching to a different ester formulated in a different oil can resolve this if the vehicle, rather than the testosterone itself, is the cause.

Subcutaneous injection of smaller-volume testosterone doses has been studied as an alternative delivery route with a slower absorption profile than standard intramuscular injection. A flatter absorption curve is a plausible reason it might reduce androgen-spike-related skin flares, but this connection has not been established with the same certainty as the core DHT mechanism above, and switching injection routes should be a decision made with a prescriber, not a self-directed change.

Estrogen, hematocrit, and effects that look like skin problems but are not

Two indirect pathways matter for skin, and they are often missed in TRT discussions.

Estradiol and skin quality. Testosterone aromatizes into estradiol in fat tissue, and for most men on TRT this stays within a normal male range. Estrogen supports skin collagen and hydration, an effect well documented in postmenopausal women where estrogen loss accelerates skin thinning. This means aggressively suppressing estradiol with an aromatase inhibitor, sometimes done to manage other TRT side effects, can paradoxically worsen skin dryness and quality. This is a real but often overlooked tradeoff worth raising with a prescriber if aromatase inhibitors are being considered.

Hematocrit and flushing. Testosterone cypionate stimulates red blood cell production. The prescribing information for testosterone cypionate identifies hematocrit above 54% as a threshold for dose reduction or treatment interruption. Elevated hematocrit can cause facial flushing and redness that patients sometimes mistake for a skin reaction or allergy. Regular monitoring of complete blood count, generally at baseline and then periodically during therapy per the prescriber's plan, is how this is caught before it becomes a bigger safety issue. This is a laboratory-driven safety parameter, not a cosmetic one, and should not be self-managed.

What is established, what is plausible, and what is not established

Established: DHT drives sebaceous gland activity and, in genetically susceptible follicles, scalp hair miniaturization. Testosterone therapy raises DHT exposure in skin. Finasteride lowers scalp DHT and is a recognized treatment for androgenetic alopecia generally. The FDA label identifies hematocrit above 54% as a threshold requiring dose action, and identifies local injection-site reactions as a known adverse effect of the injectable formulation.

Plausible but not firmly established for TRT specifically: That splitting weekly doses or switching to subcutaneous injection meaningfully reduces acne compared with standard intramuscular dosing. That finasteride or dutasteride used alongside TRT changes libido or muscle outcomes for some men. That injection technique details (needle gauge, site rotation) measurably change reaction rates. These are reasonable clinical practices grounded in pharmacokinetic logic, but the comparative evidence specific to testosterone cypionate is thinner than the core DHT mechanism.

Not established: Any precise percentage for how many TRT patients will develop acne, how much a given dose will accelerate hair loss, or how much a specific product will reduce DHT in an individual. These numbers vary across studies and populations and should not be quoted as guarantees; if a specific figure is important to a treatment decision, it should be checked against the current primary literature or discussed directly with the prescribing clinician.

Decision framework: what changes based on your history and timeline

Clinical decisions about testosterone cypionate should be based on an individualized medical evaluation by a qualified prescriber, not on this article alone. Use this information as a foundation for discussing testosterone cypionate therapy with your healthcare provider.

When to seek urgent or same-week medical attention

Sudden, severe injection-site pain, spreading redness, fever, or a hard painful lump could indicate infection or abscess rather than a routine reaction and needs prompt evaluation rather than home management. Rapidly progressive acne with scarring, or any new skin change alongside symptoms like shortness of breath, chest pain, or leg swelling (which could reflect a polycythemia-related clotting risk rather than a primary skin issue), also warrants prompt medical contact rather than waiting for a routine follow-up.